Fusion protein · Inhibitor of SARS-CoV-2 spike protein receptor-binding domain · developed by Molecular Partners
Phase 3Most advanced trial (none active)
1Registered trials
What is Ensovibep?
Ensovibep is a designed ankyrin repeat protein (DARPin)-based agent with three binding domains that target the same epitope region on the SARS-CoV-2 spike protein receptor-binding domain, blocking viral attachment and entry into human cells. It also carries a human serum albumin-binding domain that prolongs its half-life. It is studied in COVID-19.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
MP-0420
Drug type
Fusion protein
Targets
SARS-CoV-2 spike protein receptor-binding domain, human serum albumin (ALB) (binding partner it blocks)
Mechanism
Inhibitor of SARS-CoV-2 spike protein receptor-binding domain
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.